Manufacture and sale of medicines, medical supplies and cosmetics segment 82,624 5.1 - - 82,624 100.0 รวม 1,614,607 100 1,637,162 100 (22,555) (1.4) In 2018, Sales and service revenue from the Company and its
5,346 0.8 Manufacture and sale of medicines, medical supplies and cosmetics segment 82,624 5.1 - - 82,624 100.0 รวม 1,614,607 100 1,637,162 100 (22,555) (1.4) In 2018, Sales and service revenue from the
5,346 0.8 Manufacture and sale of medicines, medical supplies and cosmetics segment 82,624 5.1 - - 82,624 100.0 รวม 1,614,607 100 1,637,162 100 (22,555) (1.4) In 2018, Sales and service revenue from the
Q2/2020. Main reasons were delay to start work of new projects and award schedule was delayed by pandamic issue such as Engineering work in their headquater have been delayed. Additional, main
& ANALYSIS 1Q 2019 15 MAY 2019 U CITY PCL 1Q 2019 - MD&A (for three-month period ended 31 March 2019) 3 U CITY PCL SEGMENTAL PERFORMANCE 1Q 2019 REVENUE CONTRIBUTION BY SEGMENT 1Q 2019 REVENUE GROWTH
investment increased in the machinery and equipment segment especially for export related industries while investments in construction still contracted. Although the economy continues to show positive signs of
increase to 16.97% while Tier-1 ratio will be 13.88%. Business Segment Performance The Kiatnakin Phatra Financial Group (“the Group”) business is divided into two main areas: the commercial banking business
increase to 17.03% while Tier-1 ratio will be 13.52%. Business Segment Performance The Kiatnakin Phatra Financial Group (“the Group”) business is divided into two main areas: the commercial banking business
increase to 17.03% while Tier-1 ratio will be 13.52%. Business Segment Performance The Kiatnakin Phatra Financial Group (“the Group”) business is divided into two main areas: the commercial banking business
around unlimited data plan. AIS had seen weaken mobile revenue due to consumer spending optimization and loss of revenue from traveler segment led to -6.5%YoY decline in mobile service revenue for FY2020